GH Research publishes Phase 2a postpartum depression trial results

June 4, 2026 7:01 AM

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found